"Oral Recombinant Helicobacter pylori vaccine" won the second prize of 2013 national technological invention

Experts from the Third Military Medical University showed "oral Recombinant Helicobacter pylori vaccine" Reporter Li Wenke's "oral Recombinant Helicobacter pylori vaccine" won the second prize of 2013 national technological invention Reporter Li Wenke's "oral Recombinant Helicobacter pylori vaccine" is safe, effective and cheap, which is easy to be popularized and applied Its successful development will play a key role in effectively controlling and reducing the occurrence of the above-mentioned stomach diseases, and will produce good social and economic benefits "Oral Recombinant Helicobacter pylori vaccine" project started in 1995, and was approved to enter phase III clinical trials in December 2004 Guo Gang said that in foreign countries, none of this vaccine has achieved phase III clinical, and generally it will not progress to phase I and phase II After the phase III clinical trial of 5004 subjects, the vaccine has good safety for human body, shows strong immunogenicity in the subjects, can stimulate the body to produce specific serum IgG and saliva SIgA antibodies, and the protection rate of preventing Helicobacter pylori infection in the subjects aged 6-15 years is 72.1% Guo Gang said that this is the highest protection rate of all oral vaccines at present In March 2009, "oral Recombinant Helicobacter pylori vaccine" obtained a new drug certificate It is the first Helicobacter pylori vaccine in the world to obtain a new drug certificate The successful research and development of the vaccine has also been highly praised and affirmed by Professor Barry Marshall, the discoverer of Helicobacter pylori and Nobel Prize winner From June 22 to 25, 2009, he led a team to visit the vaccine research office of the Third Military Medical University and signed a cooperation agreement At present, the project has been transferred to Wuhu Kangwei Biotechnology Co., Ltd with an investment of 300 million yuan, the enterprise is in the process of industrialization and process enlargement The plant construction and production equipment installation are progressing smoothly, and it is expected to trial produce in the first half of this year According to reports, China is a country with a large population and stomach disease Helicobacter pylori vaccine has a large potential consumption base and a broad market There is a huge market for children's immunization with about 13 million babies born each year in China In addition to other applicable groups, the total potential demand will be more than 100 million per year According to Wu Chao, deputy director of the Department of Microbiology and biochemical pharmacy of the Pharmaceutical Department of the Third Military Medical University, the vaccine can be taken orally by people aged 6-15 years in three times, once every two weeks According to reports, in 1982, scientists found that there was Helicobacter pylori (HP) in the human stomach, which is the main "culprit" of causing gastritis, gastric ulcer and duodenal ulcer The World Health Organization (who) has confirmed that it is closely related to gastric cancer and listed it as the first level carcinogen HP is one of the bacteria with the highest infection rate in the world, with an average infection rate of 50% in the world The infection rate is higher in developing countries The number of HP infected people in China is 600 million, and 200000 people die of gastric cancer every year Human health is facing the serious threat and harm of HP At present, antibiotic treatment of HP infection is the main treatment, although it has positive clinical significance, but there are still obvious deficiencies, mainly manifested as: toxic side effects, high cost, long treatment course, poor compliance of patients, unstable curative effect, easy to relapse and so on And for a long time, Helicobacter pylori will produce strong drug resistance, simply using an antibiotic basically useless.